Search
Idronoxil
go.drugbank.com/drugs/DB04915InvestigationalIt belongs to the family of drugs called signal transduction inhibitors.
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalCompared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalIn addition, a significant improvement in lung function was seen, as measured by the volume of air exhaled by patients in one second [L1133]. … the first attack compared to patients receiving placebo [FDA Label, A31579].
Butenafine
go.drugbank.com/drugs/DB01091ApprovedButenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Glecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalpatients with moderate to severe kidney disease and those who are on dialysis [L940]. … In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors.
Pantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalAs the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists … This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus.
Products: PANTOPRAZOL HEXAL 20MG DO, PANTOPRAZOL HEXAL 40MG DOZimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving … Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOlanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigationalThe second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to … [A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548]
International brands: CO OlanzapineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeClonazepam
go.drugbank.com/drugs/DB01068ApprovedIllicitInvestigationalNow available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. … [FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.
Synonyms: 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-oneProducts: Co ClonazepamPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.